Daxor Corporation Announces Filing of Form N-2 and Seven Trial Agreements for the Daxor BVA-100 Blood Volume Analyzer
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 06/29/12 -- Daxor Corporation (NYSE MKT: DXR), a medical instrumentation and biotechnology company, has registered as an investment company. The Company filed a Form N-2 (Registration Statement Under the Investment Company Act of 1940) yesterday, June 28th.
Daxor has begun reporting as an investment company effective January 1, 2012. The Company filed a Form N-Q disclosing its schedule of portfolio holdings as of March 31, 2012.
The Company's next public report will be a Form N-CSR which will be for the six months ended June 30, 2012. This report will be filed with the SEC and sent to shareholders before the end of August 2012.
Since January 1, 2012, the Company has placed seven BVA-100 Blood Volume Analyzers on a trial basis in separate locations within the Continental United States. There are currently 65 Blood Volume Analyzers in service.
Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at .
Contact Information:
Daxor Corporation:
David Frankel
212-330-8504
(Chief Financial Officer)
Richard Dunn
212-330-8502
(Director of Operations)
Diane Meegan
212-330-8512
(Investor Relations)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.06.2012 - 06:30 Uhr
Sprache: Deutsch
News-ID 1129168
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Hospitals, Facilities and Providers
Anmerkungen:
Diese Pressemitteilung wurde bisher 347 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Daxor Corporation Announces Filing of Form N-2 and Seven Trial Agreements for the Daxor BVA-100 Blood Volume Analyzer
"
steht unter der journalistisch-redaktionellen Verantwortung von
Daxor Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
